<DOC>
	<DOCNO>NCT02229877</DOCNO>
	<brief_summary>The purpose study : determine effect stomach pH multiple dose pharmacokinetics ( PK ) AF-219 ; assess effect multiple dose AF-219 various sensory assessment ; , ass safety tolerability AF-219 .</brief_summary>
	<brief_title>A Study Assess Effect Intragastric pH Fasting Pharmacokinetics AF-219</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Must inform nature study provide write informed voluntary consent ; Able speak , read , understand English ; Healthy male female , race , 18 55 year age , inclusive ; Body mass index ( BMI ) &gt; 18.5 &lt; 32.0 kg/m2 weigh 50 100 kg ; In good general health ; Nonsmokers least 5 year ; If female childbearing potential ( i.e. , undergone hysterectomy bilateral oophorectomy ) postmenopausal ( defined menses least 12 month ) , agree use 2 form acceptable birth control ; male , and/or partner childbearing potential agree use 2 form acceptable birth control ; Any disease condition might affect drug absorption , metabolism , excretion clinically significant cardiovascular , hematological , renal , hepatic , pulmonary , endocrine , gastrointestinal , immunological , dermatological , neurological , psychiatric disease ; Clinically significant illness clinically significant surgery within 4 week administration study medication ; Any past sinus surgery , upper respiratory tract infection within 2 week dose , history hay fever time year dose take place ; History GERD , heartburn , nausea month , similar symptom require regular use antacid , use H2 histamine blocker proton pump inhibitor within 12 month Screening ; Have positive screen test Helicobacter pylorus ; QTcB &gt; 450 msec male &gt; 460 msec female ; Known suspect hypersensitivity allergic reaction component AF219 omeprazole capsule ; If female , pregnant breast feeding , positive pregnancy test pre dose ; Blood loss blood donation &gt; 550 mL within 90 day plasma donation &gt; 500 mL within 14 day administration first dose study drug ; Chronic use systemic medication ; use drug therapy know induce inhibit hepatic drug metabolism within 30 day first dose study medication ; use medication include antacid , high dose multivitamin , nutritional supplement , herbal preparation , within 14 day first dose study drug ; Past current history evidence drug alcohol abuse , use recreational soft drug ( e.g. , marijuana ) within 3 month screen , use hard drug ( cocaine , phencyclidine ( PCP ) , crack ) within 1 year screening , and/or positive screen substance abuse alcohol screen pre dose ; Ingestion grapefruit grapefruit juice within 48 hour dose administration ; Positive urine cotinine test Screening Day 1 pre dose ; Positive screen hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody ; Receipt investigational product device , participation drug research study within period 30 day ( 5 half life drug , whichever long ) first dose study medication ; Receipt investigational immunomodulator monoclonal antibody within 180 day ( 5 half life , whichever long ) first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>